Show simple item record

dc.creatorWestphal, Sylvia Paganen
dc.date.accessioned2011-07-12T18:26:49Zen
dc.date.available2011-07-12T18:26:49Zen
dc.date.created2003-07-19en
dc.date.issued2003-07-19en
dc.identifier.bibliographicCitationNew Scientist 2003 July 19; 179(2404): 24en
dc.identifier.urihttp://hdl.handle.net/10822/524045en
dc.descriptionopinionen
dc.formatArticleen
dc.languageengen
dc.source261719en
dc.subject.classificationSocial Control of Science and Technologyen
dc.subject.classificationDrugs and Drug Industryen
dc.subject.classificationGenetics, Molecular Biology and Microbiologyen
dc.subject.classificationArtificial and Transplanted Organs or Tissuesen
dc.subject.classificationResearch on Special Populationsen
dc.titleRisky businessen
dc.provenanceDigital citation created by the Bioethics Research Library, Georgetown University, for the National Information Resource on Ethics and Human Genetics, a project funded by the United States National Human Genome Research Instituteen
dc.provenanceDigital citation migrated from OpenText Livelink Discovery Server database named GenETHX to DSpace collection GenETHX hosted by Georgetown Universityen


This item appears in the following Collection(s)

Show simple item record


Georgetown University Seal
©2009—2022 Bioethics Research Library
Box 571212 Washington DC 20057-1212
202.687.3885